Drug discovery scientist and protein scientist work in the laboratory of British pharmatech company Exscientia.
2024-04-30 906词 中等
This year the giants are still going strong. On April 30th Eli Lilly, maker of a hit weight-loss treatment, delivered another dose of strong quarterly results. On May 2nd Novo Nordisk, a Danish rival with its own anti-obesity drug, is expected to do the same. Together the two are worth $1.2trn, up from $350bn three years ago. But biotech’s vitals, too, are improving. That is good news for investors, patients and the pharmaceutical industry as a whole.
经济学人和华尔街日报的文章是会员专属
请加入会员以继续阅读完整文章
成为会员后您将享受无限制的阅读体验，并可使用更多功能
免责声明：本文来自网络公开资料，仅供学习交流，其观点和倾向不代表本站立场。